Skip to main content

Table 3 Hematological parameters of male and female rats in the chronic toxicity evaluation of the CMC-AL in comparison with control. Data are presented as median (range with 95%CI) of twenty rats

From: Preclinical studies of toxicity and anti-cholangiocarcinoma activity of the standardized capsule formulation of Atractylodes lancea (Thunb.) DC

Parameters

Control

CMC-AL (mg/kg body weight)

1,000

3,000

5,000

Male

Female

Male

Female

Male

Female

Male

Female

RBCs (× 10 6 /µl) *

8.3 (7.8–8.7)

7.4 (6.9–7.8)

8.1 (7.2–9.3)

7.3 (6.9–7.8)

7.3 (7.1–8.1)*

7.0 (6.3–7.8)

7.4 (7.2–7.9)*

7.7 (4.5–9.5)

HCT (%)

60.4 (58.4–62.7)

56.2 (55.5–57.7)

59.2 (57.4–60.8)

55.7 (54.3–56.3)

59.3 (57.5–60.2)

56.2 (54.4–57.8)

60.8 (57.5–61.3)

55.9 (53.9–57.1)

Hemoglobin (g/dl) *

17.5 (16.4–18.3)

16.2 (15.6–16.7)

16.8 (16.1–17.3)*

16.0 (15.2–16.8)

14.9 (13.6–16.0)*

15.4 (15.1–16.1)

14.9 (14.2–15.8)*

15.4 (16.7–17.7)

MCV(fl or µm 3 )

62.7 (59.8–63.4)

61.8 (60.8–62.6)

63.0 (61.6–64.7)

62.0 (60.1–63.9)

62.1 (59.7–64.6)

61.5 (59.3–63.5)

63.1 (61.1–65.8)

61.3 (60.9–64.2)

MCH (pg)

18.6 (18.1–18.9)

17.9 (17.5 -18.6)

18.0 (17.2–18.9)

18.0 (17.5–18.7)

18.5 (17.9–18.9)

17.8 (17.0–19.1)

18.3 (17.5–18.8)

18.4 (17.6–19.5)

MCHC (g/dl)

31.5 (30.4–31.8)

30.5 (29.6–31.1)

31.2 (29.7–31.8)

30.1 (29.6 -30.5)

30.5 (29.8–31.0)

30.9 (29.7–31.3)

30.6 (29.2–31.6)

29.9 (28.5–31.9)

WBCs (× 10 3 /µl) *

6.9 (6.3–7.9)

5.1 (4.4–6.2)

8.1 (7.2–10.1)*

4.9 (4.4–5.7)

7.9 (7.3–9.3)*

5.0 (4.4–6.1)

6.8 (6.5–8.1)*

5.4 (5.1–6.5)

Platelets (× 10 3 /µl) *

668.4 (567.3–724.5)

679.7 (947.5–1122.1)

876.0 (768.5–1021.9)*

689.5 (622.1–693.4)

789.4 (704.6–991.3)*

729.6 (646.7–883.4)*

738.5 (699.3–1050.6)*

692.3 (643.2–711.0)

RDW (%)

24.2 (22.7–25.8)

17.5 (16.9–18.2)

23.6 (22.5–24.8)

17.2 (16.6–17.7)

23.9 (23.1–24.4)

17.1 (16.5–17.8)

24.1 (22.7–24.2)

17.6 (16.6–17.9)

PDW (%)

22.5 (20.9–23.1)

20.4 (19.8–21.3)

22.1 (20.6–22.8)

20.8 (19.5–21.7)

21.9 (20.2 -22.7)

19.9 (18.8–20.4)

22.9 (20.7–23.5)

20.6 (19.6–22.0)

MPV (fl)

12.4 (11.9–12.7)

9.0 (8.6–9.3)

12.2 (11.5–12.6)

8.5 (8.4–8.7)

12.4 (12.2–12.7)

8.8 (8.5–9.2)

12.1 (11.9–12.5)

8.9 (8.3–9.2)

PCT (%)

1.6 (1.4–1.9)

0.9 (0.8–1.0)

1.7 (1.5–1.9)

0.9 (0.8–1.0)

1.8 (1.6–2.0)

1.0 (0.8–1.0)

1.5 (1.4–1.9)

1.0 (0.7–1.2)

Neutrophils (%)

12.3 (9.5–13.8)

10.4 (7.9–11.6)

12.8 (10.2 -14.3)

9.8 (7.5–11.2)

11.9 (8.5–13.2)

9.9 (8.7–11.1)

12.5 (8.9–13.0)

10.1 (8.6–11.8)

Lymphocytes (%)

78.6 (75.3–85.2)

79.5 (76.4–85.7)

80.1 (75.3–86.2)

78.4 (72.1–85.0)

78.6 (74.6–88.2)

81.2 (78.9–85.3)

80.6 (72.9 -87.0)

81.7 (70.5–88.6)

Basophils (%)

1.2 (0.9–1.8)

1.0 (0.8–1.6)

1.1 (0.8–1.9)

1.2 (1.1–2.2)

1.0 (0.6–2.1)

1.3 (0.8–2.4)

1.3 (0.9–1.9)

1.2 (0.6–2.2)

Eosinophils (%)

0.6 (0.3–1.1)

0.6 (0.3–1.4)

0.6 (0.4–1.8)

0.5 (0.4–2.0)

0.7 (0.5–1.6)

0.6 (0.2–2.4)

0.8 (0.5 -1.9)

0.6 (0.5–2.1)

Monocytes (%)

6.5 (5.6–8.7)

5.5 (3.4–9.1)

6.2 (4.6–9.8)

4.9 (2.5–7.6)

6.8 (4.7–8.6)

6.0 (3.5–7.9)

5.8 (4.2–8.9)

5.5 (2.8–8.8)

  1. * Significantly different from the control group